Welcome to our dedicated page for ETRACS Whitney US Critical Techs ETN SEC filings (Ticker: WUCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ETRACS Whitney US Critical Techs ETN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ETRACS Whitney US Critical Techs ETN's regulatory disclosures and financial reporting.
UBS AG is offering $230,000 of Trigger Autocallable Contingent Yield Notes linked to the common stock of CrowdStrike Holdings, Inc. (CRWD) that mature on 12 July 2027. The notes are unsecured senior obligations of UBS AG’s London branch and are not listed on any exchange or covered by deposit insurance.
Key economics
- Issue price: $10.00 per note (minimum purchase = 100 notes)
- Estimated initial value (UBS models): $9.80
- Underwriting discount: $0.15 (1.5%) per note
- Principal at risk: repayment of $10 is contingent on underlying performance
- Term: ≈ 2 years (trade 9 Jul 2025, maturity 12 Jul 2027) unless called early
- Contingent coupon rate: 12.92% p.a. (≈ $0.2153 every two months) paid only if CRWD closes ≥ $308.11 (60% of initial)
- Automatic call: if CRWD closes ≥ initial level of $513.51 on any observation date prior to final valuation, investors receive par plus that period’s coupon and the note terminates
- Downside threshold / Coupon barrier: $308.11 (60% of initial level)
Pay-off profile
- Called early: investor receives $10 + accrued coupon; maximum holding period could be as short as ~2 months.
- Held to maturity & CRWD ≥ $308.11: receive principal plus final coupon.
- Held to maturity & CRWD < $308.11: repay $10 × (1 + price change). Losses are one-for-one with CRWD beyond the 40% buffer; total loss possible.
Risk highlights
- No guaranteed coupons; missing the coupon barrier on any observation date means no income for that period.
- Investors face full downside exposure below the 60% threshold and credit risk of UBS AG.
- Estimated initial value is 2.0% below issue price, reflecting dealer compensation, hedge costs and UBS’s lower internal funding rate.
- The notes are expected to be illiquid; any secondary sales will likely occur at a price materially below the issue price.
Key dates
- Bimonthly observation dates starting 9 Sep 2025; final valuation 8 Jul 2027.
- Coupons (if earned) pay two business days after each observation; maturity payment on 12 Jul 2027.
Tax treatment is uncertain; UBS intends to treat the notes as prepaid derivatives with ordinary income on coupons. Investors should review detailed risk factors and consult advisers before investing.
UBS AG is offering $230,000 of Trigger Autocallable Contingent Yield Notes linked to the common stock of CrowdStrike Holdings, Inc. (CRWD) that mature on 12 July 2027. The notes are unsecured senior obligations of UBS AG’s London branch and are not listed on any exchange or covered by deposit insurance.
Key economics
- Issue price: $10.00 per note (minimum purchase = 100 notes)
- Estimated initial value (UBS models): $9.80
- Underwriting discount: $0.15 (1.5%) per note
- Principal at risk: repayment of $10 is contingent on underlying performance
- Term: ≈ 2 years (trade 9 Jul 2025, maturity 12 Jul 2027) unless called early
- Contingent coupon rate: 12.92% p.a. (≈ $0.2153 every two months) paid only if CRWD closes ≥ $308.11 (60% of initial)
- Automatic call: if CRWD closes ≥ initial level of $513.51 on any observation date prior to final valuation, investors receive par plus that period’s coupon and the note terminates
- Downside threshold / Coupon barrier: $308.11 (60% of initial level)
Pay-off profile
- Called early: investor receives $10 + accrued coupon; maximum holding period could be as short as ~2 months.
- Held to maturity & CRWD ≥ $308.11: receive principal plus final coupon.
- Held to maturity & CRWD < $308.11: repay $10 × (1 + price change). Losses are one-for-one with CRWD beyond the 40% buffer; total loss possible.
Risk highlights
- No guaranteed coupons; missing the coupon barrier on any observation date means no income for that period.
- Investors face full downside exposure below the 60% threshold and credit risk of UBS AG.
- Estimated initial value is 2.0% below issue price, reflecting dealer compensation, hedge costs and UBS’s lower internal funding rate.
- The notes are expected to be illiquid; any secondary sales will likely occur at a price materially below the issue price.
Key dates
- Bimonthly observation dates starting 9 Sep 2025; final valuation 8 Jul 2027.
- Coupons (if earned) pay two business days after each observation; maturity payment on 12 Jul 2027.
Tax treatment is uncertain; UBS intends to treat the notes as prepaid derivatives with ordinary income on coupons. Investors should review detailed risk factors and consult advisers before investing.
UBS AG is offering $230,000 of Trigger Autocallable Contingent Yield Notes linked to the common stock of CrowdStrike Holdings, Inc. (CRWD) that mature on 12 July 2027. The notes are unsecured senior obligations of UBS AG’s London branch and are not listed on any exchange or covered by deposit insurance.
Key economics
- Issue price: $10.00 per note (minimum purchase = 100 notes)
- Estimated initial value (UBS models): $9.80
- Underwriting discount: $0.15 (1.5%) per note
- Principal at risk: repayment of $10 is contingent on underlying performance
- Term: ≈ 2 years (trade 9 Jul 2025, maturity 12 Jul 2027) unless called early
- Contingent coupon rate: 12.92% p.a. (≈ $0.2153 every two months) paid only if CRWD closes ≥ $308.11 (60% of initial)
- Automatic call: if CRWD closes ≥ initial level of $513.51 on any observation date prior to final valuation, investors receive par plus that period’s coupon and the note terminates
- Downside threshold / Coupon barrier: $308.11 (60% of initial level)
Pay-off profile
- Called early: investor receives $10 + accrued coupon; maximum holding period could be as short as ~2 months.
- Held to maturity & CRWD ≥ $308.11: receive principal plus final coupon.
- Held to maturity & CRWD < $308.11: repay $10 × (1 + price change). Losses are one-for-one with CRWD beyond the 40% buffer; total loss possible.
Risk highlights
- No guaranteed coupons; missing the coupon barrier on any observation date means no income for that period.
- Investors face full downside exposure below the 60% threshold and credit risk of UBS AG.
- Estimated initial value is 2.0% below issue price, reflecting dealer compensation, hedge costs and UBS’s lower internal funding rate.
- The notes are expected to be illiquid; any secondary sales will likely occur at a price materially below the issue price.
Key dates
- Bimonthly observation dates starting 9 Sep 2025; final valuation 8 Jul 2027.
- Coupons (if earned) pay two business days after each observation; maturity payment on 12 Jul 2027.
Tax treatment is uncertain; UBS intends to treat the notes as prepaid derivatives with ordinary income on coupons. Investors should review detailed risk factors and consult advisers before investing.
UBS AG is offering $230,000 of Trigger Autocallable Contingent Yield Notes linked to the common stock of CrowdStrike Holdings, Inc. (CRWD) that mature on 12 July 2027. The notes are unsecured senior obligations of UBS AG’s London branch and are not listed on any exchange or covered by deposit insurance.
Key economics
- Issue price: $10.00 per note (minimum purchase = 100 notes)
- Estimated initial value (UBS models): $9.80
- Underwriting discount: $0.15 (1.5%) per note
- Principal at risk: repayment of $10 is contingent on underlying performance
- Term: ≈ 2 years (trade 9 Jul 2025, maturity 12 Jul 2027) unless called early
- Contingent coupon rate: 12.92% p.a. (≈ $0.2153 every two months) paid only if CRWD closes ≥ $308.11 (60% of initial)
- Automatic call: if CRWD closes ≥ initial level of $513.51 on any observation date prior to final valuation, investors receive par plus that period’s coupon and the note terminates
- Downside threshold / Coupon barrier: $308.11 (60% of initial level)
Pay-off profile
- Called early: investor receives $10 + accrued coupon; maximum holding period could be as short as ~2 months.
- Held to maturity & CRWD ≥ $308.11: receive principal plus final coupon.
- Held to maturity & CRWD < $308.11: repay $10 × (1 + price change). Losses are one-for-one with CRWD beyond the 40% buffer; total loss possible.
Risk highlights
- No guaranteed coupons; missing the coupon barrier on any observation date means no income for that period.
- Investors face full downside exposure below the 60% threshold and credit risk of UBS AG.
- Estimated initial value is 2.0% below issue price, reflecting dealer compensation, hedge costs and UBS’s lower internal funding rate.
- The notes are expected to be illiquid; any secondary sales will likely occur at a price materially below the issue price.
Key dates
- Bimonthly observation dates starting 9 Sep 2025; final valuation 8 Jul 2027.
- Coupons (if earned) pay two business days after each observation; maturity payment on 12 Jul 2027.
Tax treatment is uncertain; UBS intends to treat the notes as prepaid derivatives with ordinary income on coupons. Investors should review detailed risk factors and consult advisers before investing.
On July 8, 2025, Longeveron Inc. (Nasdaq: LGVN) filed a Form 8-K announcing a U.S. FDA clearance of its Investigational New Drug (IND) application for laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young, healthy donor bone marrow. The clearance authorizes the Company to initiate a Phase 2 clinical trial in pediatric dilated cardiomyopathy (DCM), a life-threatening heart condition with limited treatment options. No start-date, enrollment targets, or financial terms were included in the filing. The event represents a key regulatory milestone that advances Longeveron’s lead asset into mid-stage development and broadens its clinical program into the pediatric arena. Aside from the attached press release (Exhibit 99.1), the 8-K contains no additional financial statements, earnings data, or transactional disclosures.
On July 8, 2025, Longeveron Inc. (Nasdaq: LGVN) filed a Form 8-K announcing a U.S. FDA clearance of its Investigational New Drug (IND) application for laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young, healthy donor bone marrow. The clearance authorizes the Company to initiate a Phase 2 clinical trial in pediatric dilated cardiomyopathy (DCM), a life-threatening heart condition with limited treatment options. No start-date, enrollment targets, or financial terms were included in the filing. The event represents a key regulatory milestone that advances Longeveron’s lead asset into mid-stage development and broadens its clinical program into the pediatric arena. Aside from the attached press release (Exhibit 99.1), the 8-K contains no additional financial statements, earnings data, or transactional disclosures.
On July 8, 2025, Longeveron Inc. (Nasdaq: LGVN) filed a Form 8-K announcing a U.S. FDA clearance of its Investigational New Drug (IND) application for laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young, healthy donor bone marrow. The clearance authorizes the Company to initiate a Phase 2 clinical trial in pediatric dilated cardiomyopathy (DCM), a life-threatening heart condition with limited treatment options. No start-date, enrollment targets, or financial terms were included in the filing. The event represents a key regulatory milestone that advances Longeveron’s lead asset into mid-stage development and broadens its clinical program into the pediatric arena. Aside from the attached press release (Exhibit 99.1), the 8-K contains no additional financial statements, earnings data, or transactional disclosures.
On July 8, 2025, Longeveron Inc. (Nasdaq: LGVN) filed a Form 8-K announcing a U.S. FDA clearance of its Investigational New Drug (IND) application for laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young, healthy donor bone marrow. The clearance authorizes the Company to initiate a Phase 2 clinical trial in pediatric dilated cardiomyopathy (DCM), a life-threatening heart condition with limited treatment options. No start-date, enrollment targets, or financial terms were included in the filing. The event represents a key regulatory milestone that advances Longeveron’s lead asset into mid-stage development and broadens its clinical program into the pediatric arena. Aside from the attached press release (Exhibit 99.1), the 8-K contains no additional financial statements, earnings data, or transactional disclosures.
On July 8, 2025, Longeveron Inc. (Nasdaq: LGVN) filed a Form 8-K announcing a U.S. FDA clearance of its Investigational New Drug (IND) application for laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young, healthy donor bone marrow. The clearance authorizes the Company to initiate a Phase 2 clinical trial in pediatric dilated cardiomyopathy (DCM), a life-threatening heart condition with limited treatment options. No start-date, enrollment targets, or financial terms were included in the filing. The event represents a key regulatory milestone that advances Longeveron’s lead asset into mid-stage development and broadens its clinical program into the pediatric arena. Aside from the attached press release (Exhibit 99.1), the 8-K contains no additional financial statements, earnings data, or transactional disclosures.
FAQ
What is the current stock price of ETRACS Whitney US Critical Techs ETN (WUCT)?
